IL79530A0 - Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them - Google Patents

Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them

Info

Publication number
IL79530A0
IL79530A0 IL79530A IL7953086A IL79530A0 IL 79530 A0 IL79530 A0 IL 79530A0 IL 79530 A IL79530 A IL 79530A IL 7953086 A IL7953086 A IL 7953086A IL 79530 A0 IL79530 A0 IL 79530A0
Authority
IL
Israel
Prior art keywords
naphthalenol
hmg
esters
preparation
pharmaceutical compositions
Prior art date
Application number
IL79530A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Priority to IL79530A priority Critical patent/IL79530A0/xx
Publication of IL79530A0 publication Critical patent/IL79530A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL79530A 1985-08-05 1986-07-28 Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them IL79530A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL79530A IL79530A0 (en) 1985-08-05 1986-07-28 Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/762,736 US4668699A (en) 1985-08-05 1985-08-05 Novel HMG-CoA reductase inhibitors
IL79530A IL79530A0 (en) 1985-08-05 1986-07-28 Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
IL79530A0 true IL79530A0 (en) 1986-11-30

Family

ID=25065902

Family Applications (1)

Application Number Title Priority Date Filing Date
IL79530A IL79530A0 (en) 1985-08-05 1986-07-28 Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them

Country Status (13)

Country Link
US (2) US4668699A (ko)
EP (1) EP0211416B1 (ko)
JP (1) JPS6233133A (ko)
KR (1) KR870002158A (ko)
AU (1) AU6084686A (ko)
CA (1) CA1291143C (ko)
DE (1) DE3681991D1 (ko)
DK (1) DK370486A (ko)
ES (1) ES2000842A6 (ko)
GR (1) GR862006B (ko)
IL (1) IL79530A0 (ko)
PT (1) PT83077B (ko)
ZA (1) ZA865779B (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4916162A (en) * 1986-05-05 1990-04-10 Merck & Co., Inc. Antihypercholesterolemic compounds
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4789682A (en) * 1987-03-17 1988-12-06 Merck & Co., Inc. Antihypercholesterolemic compounds
US4845237A (en) * 1987-04-15 1989-07-04 Merck & Co., Inc. Acylation process for the synthesis of HMG-CoA reductase inhibitors
PT88364A (pt) * 1987-09-02 1989-07-31 Merck & Co Inc Process for preparing novel hmg-coa reductase inhibitors
US4904692A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4994494A (en) * 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4892884A (en) * 1987-12-21 1990-01-09 Rorer Pharmaceutical Corporation Novel hmg-coa reductase inhibitors
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4866068A (en) * 1988-02-01 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
FI893004A (fi) * 1988-06-29 1989-12-30 Merck & Co Inc 5-oxygenerade hmg-coa-reduktas -inhibitorer.
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
US5200549A (en) * 1988-11-14 1993-04-06 Hoffman-La Roche Inc. Antipsoriatic agents
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5073568A (en) * 1988-11-14 1991-12-17 Hoffmann-La Roche Inc. Antipsoriatic agents
US5130306A (en) * 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) * 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
IL90847A0 (en) * 1989-06-09 1990-02-09 Merck & Co Inc 3-keto hmg-coa reductase inhibitors and pharmaceutical compositions containing them
GB8915280D0 (en) * 1989-07-04 1989-08-23 British Bio Technology Compounds
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4992429A (en) * 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
DE69026006T2 (de) * 1989-08-28 1996-10-02 Hoffmann La Roche Enzymatisches Verfahren zur Bestimmung der Analyt-Konzentration
US4946860A (en) * 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
US6630502B2 (en) 1990-05-15 2003-10-07 E.R. Squibb & Sons, Inc. Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
JP2003012607A (ja) * 2001-06-26 2003-01-15 Mercian Corp 新規なメバスタチン誘導体
CA2465854A1 (en) * 2001-11-08 2003-09-04 Merck & Co., Inc. Compounds useful in the treatment of anthrax
KR20060013632A (ko) 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
US20040119052A1 (en) * 2002-12-20 2004-06-24 Beavers William Anthony Process for preparing alpha- and beta- methyl-gamma-butyrolactone and 3-methyltetrahydrofuran
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
ES2643221T3 (es) * 2012-06-05 2017-11-21 Dsm Ip Assets B.V. Proceso para la producción de ácido 4-alcanoiloxi-2-metilbutanoico
EP4339279A3 (en) * 2017-06-15 2024-05-29 DSM IP Assets B.V. Frozen enzyme pellets
WO2019076269A1 (zh) 2017-10-16 2019-04-25 清华大学 甲羟戊酸通路抑制剂及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4376863A (en) * 1981-08-21 1983-03-15 Merck & Co., Inc. Hypocholesterolemic fermentation products
JPS5835144A (ja) * 1981-08-27 1983-03-01 Sankyo Co Ltd Ｍｂ−５３０ｂ誘導体およびその製造法
EP0094443A1 (en) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same
JPS59122483A (ja) * 1982-12-28 1984-07-14 Nippon Chemiphar Co Ltd 新規なモナコリン誘導体
EP0137445B1 (en) * 1983-10-11 1990-01-03 Merck & Co. Inc. Process for c-methylation of 2-methylbutyrates
JPH09122483A (ja) * 1995-10-31 1997-05-13 Matsushita Electric Ind Co Ltd 窒素酸化物・硫黄酸化物吸収剤

Also Published As

Publication number Publication date
KR870002158A (ko) 1987-03-30
ES2000842A6 (es) 1988-03-16
DK370486D0 (da) 1986-08-04
GR862006B (en) 1986-12-23
PT83077A (en) 1986-08-01
CA1291143C (en) 1991-10-22
EP0211416B1 (en) 1991-10-16
AU6084686A (en) 1987-02-12
JPS6233133A (ja) 1987-02-13
EP0211416A3 (en) 1987-09-23
US4851436A (en) 1989-07-25
DE3681991D1 (de) 1991-11-21
PT83077B (en) 1988-07-13
DK370486A (da) 1987-02-06
US4668699A (en) 1987-05-26
ZA865779B (en) 1987-03-25
EP0211416A2 (en) 1987-02-25

Similar Documents

Publication Publication Date Title
IL79530A0 (en) Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them
IL86464A0 (en) Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same
IL75326A0 (en) Quinolone derivatives and pharmaceutical compositions containing them
IL78079A0 (en) Sulphonylaminoethyl compounds,their preparation and pharmaceutical compositions containing them
IL79323A (en) Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
IL80404A0 (en) Quinoline derivatives,their preparation and pharmaceutical compositions containing them
GB2207922B (en) Tripeptides and pharmaceutical compositions containing them
IL79401A0 (en) Distamycin derivatives,their preparation and pharmaceutical compositions containing them
IL74244A (en) Quinoline derivatives,their preparation and pharmaceutical compositions containing them
IL104363A0 (en) 7-substituted quinolones and naphthyridones,their preparation and pharmaceutical compositions containing them
IL79025A0 (en) Quinolonecarboxylic acid esters,their preparation and pharmaceutical compositions containing them
IL86463A0 (en) Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same
IL104356A0 (en) Benzofuranyl-and thiophenylmethylthio-alkanecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL108073A0 (en) Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them
NZ217123A (en) 7-alpha-cephalosporins, pharmaceutical compositions and intermediate compounds
IL87600A0 (en) Hmg-coa reductase inhibitors,their preparation and pharmaceutical compositions containing them
IL79222A0 (en) 2-oxy-4h-3,1-benzoxazin-4-one derivatives and related compounds,their preparation and pharmaceutical compositions containing them
IL77849A0 (en) Aryldihydropyridinedicarboxylic acid ester derivatives,their preparation and pharmaceutical compositions containing them
IL79039A0 (en) 4-oxoquinolinesulfonamides,their preparation and pharmaceutical compositions containing them
IL99233A0 (en) Phosphonopyrrolidine-and phosphonopiperidine-containing pseudopeptides of the statin type,their preparation and pharmaceutical compositions containing them
IL106290A0 (en) Enzyme inhibitors,their preparation and pharmaceutical compositions containing them
IL79024A0 (en) Quinoline derivatives,their preparation and pharmaceutical compositions containing them
IL88617A0 (en) Quinoline derivatives,the preparation thereof and pharmaceutical compositions containing them
AU575386B2 (en) Pharmaceutical compositions of 4-oxo or 4-hydroxy-13-cis-vitamin
IL89286A0 (en) Quinolone compounds and pharmaceutical compositions containing them